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Abstract
Background: Pentraxin 3 (PTX3) is a soluble pattern recognition receptor with non-redundant functions in inflammation
and innate immunity. PTX3 is produced by immune and structural cells. However, very little is known about the expression
of PTX3 and its role in allergic asthma.
Objectives and Methods: We sought to determine the PTX3 expression in asthmatic airways and its function in human
airway smooth muscle cells (HASMC). In vivo PTX3 expression in bronchial biopsies of mild, moderate and severe asthmatics
was analyzed by immunohistochemistry. PTX3 mRNA and protein were measured by real-time RT-PCR and ELISA,
respectively. Proliferation and migration were examined using
3H-thymidine incorporation, cell count and Boyden chamber
assays.
Results: PTX3 immunoreactivity was increased in bronchial tissues of allergic asthmatics compared to healthy controls, and
mainly localized in the smooth muscle bundle. PTX3 protein was expressed constitutively by HASMC and was significantly
up-regulated by TNF, and IL-1b but not by Th2 (IL-4, IL-9, IL-13), Th1 (IFN-c), or Th-17 (IL-17) cytokines. In vitro, HASMC
released significantly higher levels of PTX3 at the baseline and upon TNF stimulation compared to airway epithelial cells
(EC). Moreover, PTX3 induced CCL11/eotaxin-1 release whilst inhibited the fibroblast growth factor-2 (FGF-2)-driven HASMC
chemotactic activity.
Conclusions: Our data provide the first evidence that PTX3 expression is increased in asthmatic airways. HASMC can both
produce and respond to PTX3. PTX3 is a potent inhibitor of HASMC migration induced by FGF-2 and can upregulate CCL11/
eotaxin-1 release. These results raise the possibility that PTX3 may play a dual role in allergic asthma.
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Introduction
Asthma is a chronic inflammatory condition of the airways
characterized by bronchial hyperresponsiveness, infiltration of
inflammatory cells, and airway remodeling. Increased airway
smooth muscle mass and deposition of extracellular matrix (ECM)
proteins, is an important feature of airway remodeling [1].
Cumulative evidence suggest that airway smooth muscle cells
(ASMC) are not only the target for but also a rich source of
different pro-asthmatic factors [2]. These studies indeed suggest
that ASMC may be classified as ‘inflammatory-like’ cells by virtue
of their capacity to produce and respond to multiple pro-
inflammatory mediators [2,3,4]. These mediators in turn modulate
the ASMC functions such as cell proliferation, migration, and
matrix production, eventually leading to airway remodeling.
Importantly, it is now evident that ASMC can directly respond
to inhaled environmental factors via mechanisms that are either
immune-mediated such as both high- and low-affinity IgE
receptors [5,6,7,8,9], or in an immune-independent fashion such
as protease activated receptor-2 (PAR2) or calreticulin [10,11],
summarized in [12]. Targeting ASM, therefore, presents an
attractive treatment regimen for chronic airway inflammatory
diseases.
Pentraxin 3 (PTX3) is a newly discovered member of the long
pentraxins, and an acute phase protein that has emerged as a new
serological marker reflecting tissue inflammation and damage
under diverse human pathological conditions [13,14], such as
acute myocardial infarction [15], small vessel vasculitis [16],
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and tuberculosis [19,20]. PTX3 can be produced by a variety of
cells at the site of infection or inflammation. These include
macrophages, dendritic cells [21,22], neutrophils [23], endothelial
cells [24], fibroblasts [25], epithelial cells [26], and vascular
smooth muscle cells [27]. As a soluble pattern recognition
receptor, PTX3 binds to and plays non-redundant protective role
against selected pathogens, such as fungi, bacteria and virus
[28,29,30]. It orchestrates complement activation, and displays
opsonic activity by promoting phagocytosis and clearance of the
pathogens. PTX3 is also a component of ECM protein required
for the assembly of the cumulus oophorus and female fertility [31],
thereby linking its function to the ECM remodeling. Moreover,
PTX3 interacts with other biologically active molecules, such as
fibroblast growth factor-2 (FGF-2) [32] and P-selectin [33].
Considering an ‘inflammatory-like’ phenotype of ASMC [2], we
hypothesized that PTX3 may also be involved in airway diseases
such as allergic asthma. Thus, we first investigated the expression
of PTX3 in bronchial biopsies of asthmatic patients, and then
analyzed the production of PTX3 in human primary ASMC and
epithelial cells (EC) in vitro. We further investigated the possible
effects of recombinant human PTX3 on ASMC functions such as
inflammatory mediator release, cell migration, and proliferation.
Results
Expression of PTX3 is increased in bronchial biopsies of
allergic asthmatic patients
Bronchial biopsy specimens from healthy controls (n=10) and
subjects with allergic asthma (n=27; 9 with mild, 10 with
moderate, and 8 with severe asthma) were used for immunohis-
tochemistry staining using mAb anti-human PTX3. Positive PTX3
immunoreactivity was detected in all cases in the epithelium,
bronchial mucosa inflammatory infiltrating cells and ASM cell
layers (Figure 1 A, C, E and G). Substitution of the first Ab with
matched rat-IgG2b control eliminated the positive signal,
demonstrating the specificity of the analysis (Figure 1 B, D, F
and H).
Interestingly, since PTX3 was abundantly present at sites of
ASM bundle, we performed semi-quantitative assessment through
blind grading [34]. PTX3 staining intensity was significantly
increased in asthmatic groups compared to healthy controls
(Figure 1 I, P,0.001). A significantly higher staining intensity was
found in mild (Figure 1 C) (P,0.05), moderate (Figure 1 E)
(P,0.01) or severe (Figure 1 G) (P,0.05) asthmatic subjects
compared to healthy controls (Figure 1 A). Furthermore,
comparing the mean values of PTX3 staining intensity in the
subgroups of asthmatic subjects revealed that severe and moderate
group had higher intensity than mild asthmatic group without
reaching statistical significance (P.0.05).
PTX3 protein is highly expressed by human ASMC
(HASMC) in vitro
Lung EC lines have been previously shown to express PTX3
[26]. Similarly, PTX3 immunoreactivity was observed in our study
in both ECs and HASMC within bronchial biopsies of asthmatic
and healthy donors (Figure 1). We then decided to compare PTX3
release from HASMC (n=4 donors) with that in human airway
ECs (n=4 donors). Under similar culture conditions and the same
cell number, levels of PTX3 released from cultured HASMC was
far greater than the airway EC at the baseline (mean value more
than 36-fold) or upon TNF stimulation (mean value more than
115-fold) (Figure 2), suggesting that HASMC are one of the main
producers of PTX3 in the airways.
The effect of proinflammatory, Th2, and Th1 cytokines on
PTX3 release from HASMC
Considering an inflammatory milieu in allergic asthma [35], we
then investigated the effect of proinflammatory, Th2, and Th1
cytokines on PTX3 protein release by HASMC. TNF and IL-1b
induced a significant increase in PTX3 protein release from
HASMC. However, HASMC stimulated with Th2 (IL-4, IL-9 and
IL-13), Th1 (IFN-c), or Th17 (IL-17) cytokines showed no
significant effect on PTX3 release (Figure 3 A, and data not
shown).
The central role of TNF in lung inflammation is not only
supported by animal models, but also human studies [36,37]. So,
we further characterized the dose or time course effect of TNF on
PTX3 expression by HASMC. A statistically significant increase in
PTX3 protein release from HASMC occurred with 0.1 ng/ml
(*P,0.05), 1 ng/ml (***P,0.001), and 10 ng/ml (***P,0.001)
concentration of TNF (n=5) (Figure 3 B). Furthermore, time
course assay showed that PTX3 protein release by HASMC was
time-dependent and reached a maximum at 48 h in response to
TNF (10 ng/ml) stimulation (Figure 3 C).
Recombinant PTX3 induces CCL11/eotaxin-1 but not
TGFb1, CXCL8/IL-8, or IL-6 protein release from HASMC
Because the functions of PTX3 are not yet completely defined,
we explored whether PTX3 could be an inducer of inflammatory
mediators. To test this hypothesis, serum-deprived HASMC were
stimulated with a graded concentration of human recombinant
PTX3 (10–500 ng/ml). A statistically significant increase in
eotaxin-1/CCL11 release from HASMC occurred with 50, 100,
and 500 ng/ml PTX3 at 24 h (P,0.05, Figure 4 A). However,
PTX3-stimulated HASMC showed no statistical significance in
TGFb1 (Figure 4 B), IL-6 (Figure 4 C) or CXCL8/IL-8 release
(p.0.05, n=3; data not shown). Taken together, the above data
demonstrate that PTX3 can induce CCL11/eotaxin-1 production
in HASMC but fails to affect TGF-b1, IL-6 or CXCL8/IL-8.
Recombinant PTX3 inhibits FGF2-induced chemotaxis
but not proliferation in HASMC
PTX3 was previously shown to play an important role in tissue
remodeling and matrix assembly [38]. We therefore investigated
its role in HASMC migration as a surrogate marker of airway
tissue remodeling. Migration of HASMC was slightly increased by
PTX3 alone (50 ng/ml, 1.5060.40- fold and 100 ng/ml,
1.5160.32-fold, P,0.05). Platelet-derived growth factor (PDGF,
10 ng/ml), used as positive control, significantly increased the
HASMC chemotaxis (3.0260.65-fold, P,0.001) compared to the
medium control (Figure 5 A).
Previous observations have shown the ability of PTX3 to bind
FGF-2, thus acting as an FGF-2 antagonist [32,39]. Furthermore,
FGF-2 is known to contribute to HASMC proliferation and
migration ability that are believed to be major contributors to
airway remodeling in asthma [40]. On this basis, we further
investigated the capacity of PTX3 to affect FGF-2-dependent
HASMC migration. As showed in. Figure 5 B, FGF-2 significantly
increased migration of HASMC, with an optimal response at
20 ng/ml (3.7160.71-fold, P,0.001 compared to the medium).
Concentration of PTX3 between 10–100 ng/ml significantly
inhibited the effect of FGF-2 on HASMC migration (Figure 5
C, #P,0.001 compared to FGF-2 alone (20 ng/ml, n=3).
We then determined whether PTX3 modulates FGF-2 induced
HASMC proliferation. Using [
3H]-thymidine incorporation assays
or Alamar Blue
TM assay, we found that the PTX3 was incapable
to modulate HASMC proliferation alone in contrast to PDGF
Pentraxin 3 and Airway Smooth Muscle Cell
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Furthermore, FGF-2 stimulated HASMC showed significant
proliferation as expected. However, FGF-2-mediated HASMC
proliferation was not affected by addition of PTX3 (data not
shown).
Taken together, these data demonstrate that PTX3 has the
ability to inhibit FGF2-induced migration of HASMC at least in
vitro suggesting its role as potential protective mechanism against
remodelling observed in asthma.
Discussion
The present study is the first description of PTX3 expression in
patients with allergic asthma. A significantly higher expression of
PTX3 within the ASMC area was observed in mild, moderate,
and severe asthmatics compared to healthy donors. PTX3 is
abundantly expressed within ASM bundle and epithelial cell layers
as well as inflammatory cell infiltrate. Furthermore, at least in vitro,
primary HASMC produced higher levels of PTX3 at the baseline
and upon TNF stimulation compared to epithelial cells, suggesting
that HASMC are one of the major sources of this mediator in the
airways. We also showed that PTX3 can be up-regulated by TNF,
but not IFNc, IL-17, IL-4, IL-9, or IL-13 in HASMC. Moreover,
we showed that the PTX3 induces CCL11/eotaxin-1 release, but
not IL-6, CXCL8/IL-8, or TGF-b and counteracts FGF-2-
induced HASMC migration. Taken together, our data suggest a
potential dual role of PTX3 in allergic asthma by enhancing
airway inflammation via local CC chemokine expression from
HASMC; and down regulating the remodeling by counteracting
FGF-induced HASMC migration.
PTX3 is pleiotropic molecule that has been shown to have
antibody like functions such as opsonizing properties, activating
and regulating complement and binding to pathogens [13].
Moreover, a potential role of PTX3 in the inflammatory response
is suggested by elevated PTX3 levels in plasma of patients with
sepsis [41], acute myocardial infarction [15], or chronic kidney
disease [18]. Interestingly, PTX3 knockout mice are susceptible to
pulmonary aspergilosis [29], whereas PTX3 transgenic mice
display greater resistance to cecal ligation and puncture [42].
The human PTX3 gene is located on the chromosome 3q24–28
[43], the region which has been linked to the phenotype related to
Der P1 allergen-specific IgE, and total serum IgE in humans [44].
Therefore, an association between PTX3 levels and allergic airway
disease may not be denied. The current study adds to this notion
by clearly showing that allergic asthmatic patients express higher
PTX3 levels compared to healthy controls. In COPD, an
obstructive inflammatory disease with some features similar to
asthma, PTX3 expression was found to be reduced in lung sections
of patients which correlated with FEV1 (a marker for small airway
obstruction); while the PTX3 expression in induced sputum in
COPD patients did not have any correlation with FEV1 [45].
Figure 1. PTX3 is increased in human allergic asthma. Positive PTX3-immunoreactivity is shown from representative bronchial biopsies of
healthy control (A), mild (C), moderate (E), and severe (G) asthma subjects. No staining was observed in isotype-matched control mAbs in
corresponding biopsies (B, D, F, or H). The scores of PTX3 immunoreactivity is shown (I). ###P,0.001 all allergic asthmatic groups vs healthy
control; *P,0.05, **P,0.01 each asthmatic subgroup vs healthy control. (Original magnifications 6100). Red staining indicates PTX3 expression.
doi:10.1371/journal.pone.0034965.g001
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sputum of COPD patients compared to controls [46]; whereas the
PTX3 knockout mice showed no difference in cigarette smoke-
induced pulmonary inflammation, emphysema, and body weight
changes compared to the wild-type mice [47]. Therefore, a clear
role of PTX3 in the pathogenesis of COPD remains yet to be
established.
The reason why PTX3 is highly expressed within the airway of
asthmatics remains unknown, but there are at least two possible
explanations. First, emerging evidence suggests PTX3 as an
important structural component of ECM that plays a crucial role
in sustaining its stability [13,14,48]. In particular, PTX3 is
involved in the organization of ECM by cross-linking hyaluronan
via interaction with TNF-stimulated gene 6 (TSG6) and Inter-a-
trypsin inhibitor (IaI) [49,50]. In agreement with the role of PTX3
in matrix organization, our IHC staining showed a significant
PTX3 staining within the ASM bundles of asthmatic bronchial
tissue compared to healthy donors, which may provide another
possible explanation of airway remodeling observed in asthma.
Second, PTX3 may potentially contribute to airway inflammation
and subsequent remodeling. Furthermore, PTX3 enhanced
CCL11/eotaxin-1 release in HASMC, chemokine that plays an
important role in eosinophil airway inflammation [51], and
remodeling [52].
However, it is worth mentioning that CCL11/eotaxin-1, besides
its role in attracting eosinophils, can exert a specific regulatory
function of neutrophil recruitment in vivo as has been shown in a
mouse model of endotoxemia [53] via probable down-regulation
of CXC chemokine CXCL8/IL-8 [54]. In light of prior evidence
and present data, it is tempting to speculate that PTX3-mediated
CCL11/eotaxin-1 release may down-regulate exaggerated neu-
trophilic inflammation by suppressing CXC chemokine release
during acute inflammation, hence creating a negative feedback to
establish tissue homeostasis especially in severe asthma that is
characterized by more neutrophilic infiltrates [55]. In agreement
with this possibility, Mantovani and colleagues reported recently
that PTX3 dampens neutrophil recruitment in vivo via a P-selectin
dependent mechanism [33]; and previous data demonstrated that
PTX3 knockout mice develop more myocardial damage associ-
ated with more neutrophil infiltration in a model of cardiac
ischemia reperfusion injury [56]. These data suggest a potential
role of PTX3 in down regulating neutrophilic airway inflamma-
tion in allergic asthma. Taken together, it is plausible that on one
Figure 2. HASMC produce enhanced PTX3 in vitro compared to
airway EC. (A) 75–80% confluent HASMC or ECs were growth arrested
by FBS deprivation for 48 h, and stimulated in fresh FBS-free medium
containing TNF (10 ng/ml) or medium alone. Supernatants were
collected at 24 h, and PTX3 was quantified using ELISA. #P,0.0001
PTX3 protein release from HASMCs versus from airway ECs by ANOVA.
doi:10.1371/journal.pone.0034965.g002
Figure 3. Cytokines induce PTX3 expression in HASMC in vitro.
(A) PTX3 protein release from HASMC stimulated with proinflammatory
(IL-1b, TNF, 10 ng/ml), Th2 (IL-4, IL-9, 10 ng/ml, or IL-13, 100 ng/ml), or
Th1 cytokines (IFN-c, 100 U/ml) for 24 h (n=3). (B) PTX3 protein release
was measured in response to increasing concentrations of TNF at 24 h
(n=5), or (C) at various time-points in presence of TNF (10 ng/ml)
(n=3). *p,0.05, ***p,0.001 compared to medium group.
doi:10.1371/journal.pone.0034965.g003
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neutrophilic response [45], whereas enhanced PTX3 expression in
asthmatics may embark on an eosinophilic inflammation poten-
tially via inducing eotaxin-1/CCL11 expression in airway
structural cells. More studies are needed further to investigate
these possibilities.
We also found that PTX3 significantly inhibits FGF-2-induced
chemotaxis in HASMC. Furthermore, in contrast with previous
study in vascular smooth muscle cells [39], we did not find any
effect of PTX3 protein on HASMC proliferation, suggesting that
PTX3 effect is cell specific. Although PTX3 at higher doses by
itself tend to induce ASM migration, it attenuates the FGF-2-
induced migration. It may be plausible that the locally-produced
PTX3 facilitates immune inflammatory cell recruitment, while
counteracts the effects of FGF-2 in inducing migration of ASM
itself. Moreover, since PTX3 has been shown to act as an
antagonist of FGF-2 by others [32,39], it may be plausible that the
inhibitory effect on migration is selective and specific to FGF-2-
induced migration. We are exploring these hypotheses further by
extensive in vitro studies and by employing PTX3 knockout mouse
model. Besides EC that is the main source of FGF-2 in asthmatic
airways, inflammatory cells mobilized into the airways such as
eosinophils, macrophages, T-cells, mast cells are also potent
producers of FGF-2 [40]. FGF-2 is known to be released directly
following allergen-induced degranulation of mast cells which may
cause HASMC migration [57]. On this basis, it is enticing to
speculate that PTX3 released from HASMC, as well as others
sources, may have a regulatory role in smooth muscle migration
and thus airway remodeling.
In conclusion, this novel study demonstrated an increased
PTX3 expression in bronchial biopsies of allergic asthmatics
compared to healthy controls. Considering HASMC as one of the
major cell types in the airway, constitutive expression and
inducible PTX3 produced from this source may play a dual role
in inflammatory and airway remodelling process in allergic
asthma.
Some of the results of these studies have been previously
presented in American Thoracic Society International Conference
and reported in the form of an abstract online.
Materials and Methods
Ethics statement
Human airway smooth muscle cells (HASMC) were obtained
from surgical patients following the receipt of written informed
consent in accordance with procedures approved by the Human
Research Ethics Board of the University of Manitoba, Winnipeg,
Canada. Bronchoscopy to obtain lung tissue (for immunohisto-
chemistry) was performed in accordance with procedures
approved by the Human Research Ethics Board of Laval
University, Quebec, Canada, following the receipt of the subjects’
written informed consent. The current study was approved by the
research ethics boards of the University of Manitoba, Winnipeg,
and the Laval University, Quebec, Canada.
Reagents
Recombinant human TNF, IL-1b, IL-4, IL-9, IL-13, IFN-c,
FGF-2, PTX3 proteins, and ELISA kits for human PTX3 were
purchased from R&D Systems (Minneapolis, MN). Monoclonal
rat anti-PTX3 (MNB1) was purchased from ALEXIS Biochem-
icals (Lausen, Switzerland). All other reagents were procured from
Sigma-Aldrich Canada Ltd. (Oakville, ON), unless specified.
Subjects
Asthmatic subjects were fulfilling the American Thoracic
Society selection criteria [58]. Mild asthmatics had an FEV1 of
.80% predicted, used no inhaled corticosteroids (CS), had
symptoms ,2 days per week, and rare exacerbations. Moderate
asthmatics used inhaled CS on a daily basis and had an FEV1 of
.50% predicted and used less than 1000 mg fluticasone/day.
Furthermore, moderate asthmatics have a history of emergency
department (ED)/urgent care visits or systemic steroid use within
the past year. Severe asthmatics needed treatment with high dose
of inhaled CS (.1000 mg fluticasone/day) or systemic CS. All
asthmatic subjects were atopic with at least one positive response
to common allergens on allergy skin prick tests. In the month
preceding the study, none of the subjects reported a respiratory
infection or an increase in asthma symptoms. Some subjects who
had the smoking history had quit at least three months. Healthy
subjects were non-atopic non-smokers with no history of asthma,
respiratory disease or atopy, except one who had a smoking history
and had quit 2.5 years ago. All healthy subjects showed normal
pulmonary function testing and a negative methacholine chal-
lenge. Subjects’ characteristics are shown in Table 1.
Immunohistochemistry
Paraffin sections were stained with rat anti-human PTX3 mAb
or control IgG2b followed by secondary biotin goat anti-rat IgG
and streptavidin-alkaline phosphatase developed by fast red as
described earlier [59]. Briefly, formalin-fixed tissues were paraffin
Figure 4. Recombinant human PTX3 induce cytokine release from HASMC. Eotaxin-1/CCL11 (A), TGF-b1 (B), and IL-6 (C) proteins were
measured by ELISA upon 24 h stimulation of serum deprived HASMCs with graded concentrations of recombinant PTX3 (*P,0.05, **P,0.01 and
***P,0.001 compared with medium group).
doi:10.1371/journal.pone.0034965.g004
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in xylene, and rehydrated through graded concentrations of
alcohol to water and then boiled with microwave for 10 min in
sodium citrate buffer (pH, 6.0) for antigen retrieval. Sections were
washed and then incubated with blocking solution (5% goat
serum, 1% BSA, 0.1% cold fish skin gelatin in PBS) for 60 min at
room temperature. Rat anti-human PTX3 mAb or control mouse
IgG2b (both at 10 mg/ml) were added, and sections were
incubated overnight at 4uC. Slides were then washed twice with
PBS followed by incubation for 1 h at room temperature with
biotin-conjugated goat anti-rat IgG (Jackson ImmunoResearch
Laboratories, Inc. West Grove, PA). Slides were then washed
extensively with PBS and incubated with streptavidin-alkaline
phosphatase for 30 min at room temperature. After washing with
PBS, the slides were developed using Fast Red and counterstained
with Mayer’s hematoxylin. Positive cells stained red after
development with Fast Red (Sigma-Aldrich Canada Ltd., Oak-
ville, ON). Isotype-matched control mAb was used for negative
control. Semi-quantitative assessment of specimens were per-
formed by three independent observers and a pathologist in a
blinded manner as previously described [34]: 0, absent or faint
staining of an occasional ASM bundle only; l+, faint staining of
several ASM bundle; 2+, moderate intensity staining of most ASM
bundle; 3+, intense staining of most ASM bundle and 4+ intense
staining of all ASM bundle.
Figure 5. PTX3 abrogates FGF-2 induced HASMC migration. Boyden upper chamber-seeded HASMC were exposed to graded concentrations
of (A) PTX3, (B) FGF-2, and (C) PTX3 plus FGF-2 (20 ng/ml) in lower compartment for 4 h. The migrated cells were quantified by light microscope
(magnification, 6200). Migration is expressed as fold increase relative to medium control (D, E, and F). *P,0.05, ***P,0.001 vs medium control.
#P,0.001 compared to FGF-2 (20 ng/ml). n=3.
doi:10.1371/journal.pone.0034965.g005
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HASMC were obtained as described previously [59,60,61] from
macroscopically healthy segments of the trachea after lung
resection from surgical patients in accordance with procedures
approved by the Human Research Ethics Board of the University
of Manitoba, Winnipeg, Canada. Primary HASMC were isolated
from explants. HASMC retain smooth muscle-specific actin,
SM22, calponin protein expression, and mobilize intracellular
Ca
2+ in response to acetylcholine [60], and were used at passages
3–5. HASMC were grown on uncoated plastic dishes in complete
DMEM (DMEM supplemented with 100 mg/ml streptomycin,
100 U/ml penicillin, and 10% fetal bovine serum). Unless
otherwise mentioned, cells were grown to a subconfluent
(,70%) condition and serum starved to synchronize for 48 h in
Ham’s F12 supplemented with 100 mg/ml streptomycin, 100 U/
ml penicillin, and 1X ITS (5 mg/ml insulin, 5 mg/ml transferrin,
and 5 ng/ml selenium) before each experiment. Primary bronchial
epithelial cells (EC) were isolated from biopsies obtained from
healthy controls by using previously described techniques [62,63].
Briefly, epithelial cells were isolated from bronchial biopsies
obtained by bronchoscopy, and were characterized by immuno-
fluorescence and flow cytometry using anti-cytokeratin antibody
from Calbiochem (San Diego, CA). This identification confirmed
the purity of the bronchial cell culture as we previously described
[62,63]. EC were cultured in DMEM supplemented with 100 mg/
ml streptomycin, 100 U/ml penicillin, and 10% fetal bovine
serum.
ELISA
PTX3 ELISA was performed according to the protocol
provided by the manufacturer (R&D Systems, Minneapolis,
MN). Sensitivity was 20 pg/ml for PTX3. IL-6, IL-8, TGFb,
and eotaxin-1/CCL11 ELISA was performed in-house using
matched Abs from R&D Systems. Sensitivity was IL-6 (7.6 pg/ml),
CXCL8/IL-8 (7.6 pg/ml), TGF-b (15 pg/ml), and CCL11/
eotaxin-1 (10 pg/ml).
Proliferation and chemotaxis assay
Cell proliferation was examined by using
3H-thymidine
incorporation [64], cell counting, and Alamar blue assays. Cell
migration was analyzed according to the previously described
using Boyden chamber assay [65]. Briefly, 48 h serum-starved cells
were detached from the culture plate using trypsin (0.5 mg/ml)-
EDTA (0.2 mg/ml) solution (Invitrogen Canada Inc., Burlington,
ON) and resuspended in Ham’s F12 medium containing 100 mg/
ml streptomycin, 100 U/ml penicillin, and 1X ITS. A polycar-
bonate membrane of 8 mm pore size (Neuroprobe, Gaithersburg,
MD, USA) was coated with 0.01% collagen type-I in 0.01N HCl
solution (Sigma). A 50 ml aliquot of HASMC (5610
4 cells/ml) was
added to the upper chamber of modified Boyden chamber
apparatus (Neuroprobe). In the lower chamber, FGF-2, PDGF, or
PTX3 were added as a chemoattractant to the same media as the
upper chamber. After 4 h of incubation at 37uC in humidified 5%
CO2 incubator, the membranes were peeled-off. Cells on the
upper side of the membrane were scraped off and the cells
migrated to the lower side were fixed and stained with
HemacolorH stain set (EMD Millipore, Billerica, MA, USA) The
number of migrated cells was counted in four-five random fields
under620 magnification by phase contrast microscope (Carl Zeiss
Canada Ltd., Toronto, ON).
Statistical analysis
Data obtained from experiments performed in triplicate and
repeated at least three times was represented as means 6 SEM.
Differences among groups were analyzed using unpaired t-tests or
ANOVA together with a post-hoc Bonferroni analysis. Non-
parametric data were analyzed using the Kruskal-Wallis test
followed by the Mann-Whitney U-test. P values were considered
significant at 0.05 levels.
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Table 1. Clinical characteristics of the subjects.
Category Subcategory Healthy controls Mild asthma Moderate asthma Severe asthma
Number (n) 10 9 10 8
{Age (years) 2461.5 2461.6 3364.5 3965.9
Sex Male 7 4 2 1
Female 3 5 8 7
Smoking status NS 8 6 9 5
Ex 2 3 1 3
S00 0 0
Atopy Yes 0 9 10 8
No 10 0 0 0
{FEV1 (%) 98.562.8 96.064.4 86.366.7 78.966.0
{PC20 (mg/ml) 111.4618 1.760.7 0.760.5 -
Asthma medication ICS (mg) - - 437.56100.2 1187.56277.2
LABA - - - Yes
{Data are expressed as mean 6 SEM.
NS: Non smoker; Ex: Ex-smoker; S: Smoker.
FEV1: forced expiratory volume in 1 second.
LABA: Long acting b2-agonists.
doi:10.1371/journal.pone.0034965.t001
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